





B. Richard Vogt, Ph.D.

Vice President Business Development





Dr. Robert H. Harris Federal Research Consultants 2139 Route 35 Holmdel, NJ 07733

Dear Dr. Harris:

Thank you very much for your letter of September 15, 1997, regarding ADD 234037, a novel antiepileptic drug with neuroprotective properties.

Our business development staff has reviewed the data presented. While they found the information to be very interesting, it unfortunately does not fit within our current strategic focus.

I would like to thank you for thinking of Fujisawa USA and wish you success with your efforts to license this product.

Sincerely,

B. Richard Vogt, Ph.D.

Brichard Vogt

1344/lms

Post-it® Fax Note	7671	Date 11 3 # of pages 2
TOAL		From Republic
Co./Dept.		Co.
Phone #		Phone #
Fax #		Fax#

